Holen Sie sich die Stockscreener-App
59.03
3.40%
-2.08
Handel nachbörslich:
59.23
0.20
+0.34%
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Corcept Therapeutics (NASDAQ:CORT) Trading Up 7.9%Here's What Happened - MarketBeat
Cushing's Syndrome Market Expected to Hit US$ 291.1 million - openPR
Here’s Why Analysts Are Bullish on Corcept Therapeutics Incorporated (CORT) - Insider Monkey
Ovarian Cancer Drugs Market Analysis: Segments, Drivers, - openPR
Here's What Could Help Corcept (CORT) Maintain Its Recent Price Strength - MSN
Corcept Therapeutics Incorporated (CORT): Why Should You Buy This Growth Stock For The Next 5 Years? - Yahoo Finance
Hennion & Walsh Asset Management Inc. Trims Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Burney Co. Increases Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Sells $111,188.00 in Stock - MarketBeat
Corcept Therapeutics director Daniel Swisher sells $111,188 in stock By Investing.com - Investing.com Canada
Corcept Submits Application for Another Cushing's Syndrome Drug - MSN
Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
JPMorgan Chase & Co. Has $11.71 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Cushings Syndrome Market Is Booming Worldwide 2024-2031 | Corcept Therapeutics Inc., HRA Pharma - EIN News
Range Financial Group LLC Buys New Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Therapeutics Incorporated (CORT) Surged on Strong Results and Increased Guidance - Yahoo Finance
Corcept Therapeutics officer sells shares for $251,950 - Investing.com India
Corcept Therapeutics officer sells shares for $251,950 By Investing.com - Investing.com Australia
Sean Maduck Sells 20,000 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock - MarketBeat
Corcept Therapeutics' chief business officer sells shares worth $555,551 By Investing.com - Investing.com Nigeria
Corcept Therapeutics' chief business officer sells shares worth $555,551 - Investing.com
Corcept Therapeutics president sells $1 million in stock By Investing.com - Investing.com Canada
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $65.25 Consensus PT from Analysts - Defense World
Corcept asks FDA to OK relacorilant for Cushing’s syndrome - Cushing's Disease News
Analysts Set Corcept Therapeutics Incorporated (NASDAQ:CORT) Target Price at $65.25 - MarketBeat
Here's Why Corcept Therapeutics (NASDAQ:CORT) Has Caught The Eye Of Investors - Simply Wall St
Corcept files NDA for new Cushing's syndrome drug By Investing.com - Investing.com Canada
Corcept Therapeutics Submits New Drug Application for Cushing's Sydrome Treatment - MarketWatch
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism - Business Wire
Corcept Therapeutics Submits FDA Application for Breakthrough Cushing's Syndrome Treatment Relacorilant - StockTitan
Principal Financial Group Inc. Lowers Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
MML Investors Services LLC Invests $317,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Will Corcept Therapeutics Incorporated (CORT) Make You Rich In 2025? - Yahoo Finance
10 Stocks That Will Make You Rich In 2025 - Insider Monkey
Hypercortisolism research fuels Corcept’s DTC awareness campaign - MM+M Online
What is Zacks Research's Forecast for CORT FY2025 Earnings? - MarketBeat
Abortion Drugs Market Growth in Future Scope 2024-2031 | Corcept - openPR
Zacks Research Issues Negative Forecast for CORT Earnings - MarketBeat
Geode Capital Management LLC Grows Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Wellington Management Group LLP Trims Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
World Investment Advisors LLC Takes Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept’s dazucorilant fails to slow ALS progression in clinical trial - ALS News Today
Corcept Therapeutics’ Cushing’s syndrome therapy shows promise in Phase III trial - Yahoo Finance
Corcept Therapeutics Incorporated (NASDAQ:CORT) Short Interest Down 7.0% in November - MarketBeat
Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism - BioSpace
Relacorilant shows promise in long-term hypercortisolism study - Investing.com
Corcept's Phase 3 Study Shows Breakthrough Blood Pressure Results for Relacorilant in Long-term Treatment - StockTitan
Stifel Financial Corp Buys 20,546 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
Corcept Shares Rise More Than 60% in Three Months: Here's Why - MSN
State Street Corp Has $162.87 Million Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) - MarketBeat
1.44%
7.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):